Research-based biopharmaceutical industry on the TRIPS waiver discussions at WTO Ministerial Conference (MC12)
The associations representing the global research-based biopharmaceutical industry reaffirm that weakening the intellectual property (IP) framework as proposed in the “Quad compromise” is unnecessary and harmful to innovation. An IP waiver does not address inequitable access to COVID-19 vaccines and will put global health security at risk. It will undermine innovation and industry’s ability to partner, invest at risk, and respond quickly to future pandemics.
Read more
It’s a great moment for the hematology community to stand up and advocate for explicit policy action on blood cancers...
Read more
Back innovation, boost access
Innovation is only meaningful if patients get access to it. That’s why we are stepping up measures to help deliver faster, more equitable access to medicines for millions of patients across the EU. Read more
IML, the organization representing the originator pharmaceutical industry in Luxembourg, is hiring an experienced...
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.